摘要
胞外-5’-核苷酸酶(ecto-5’-NT、 5’-NT、 eN、 CD73)是一种膜酶,其主要由AMP腺苷的胞外产物构成。Ecto-5''-NT是由多种类型的癌症细胞过表达,导致了肿瘤微环境腺苷浓度的提高。发现腺苷在癌症机理中也很重要,对抗肿瘤T细胞和巨噬细胞表现出较强的免疫抑制作用,促进心血管生成和细胞粘附。这些作用帮助细胞生长与发展。提示ecto-5’-NT的抑制导致肿瘤微环境中胞外腺苷浓度的降低,这将直接影响肿瘤细胞并致使肿瘤恶性细胞易受宿主防御系统的影响。此机制被提议为癌症治疗的有希望的新靶点。本综述的目的是为了探索ecto-5’-NT生化和结构特征,包括分子模拟活性部位的简要分析,分子模拟是评估这种酶的抑制是否能够确实代表治疗癌症的可行性策略的一种方法。对在癌症治疗期间可能被用作ecto-5’-NT靶点的已知抑制剂和可能的原型也进行了讨论。
关键词: 腺苷,癌症治疗,胞外-5’-核苷酸酶,酶抑制,新靶点,嘌呤信号。
Current Medicinal Chemistry
Title:Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Volume: 22 Issue: 15
Author(s): Patricia Frasson Corbelini, Fabricio Figueiro, Gustavo Machado das Neves, Saulo Andrade and Daniel Fabio Kawano, Ana Maria Oliveira Battastini and Vera Lucia Eifler-Lima
Affiliation:
关键词: 腺苷,癌症治疗,胞外-5’-核苷酸酶,酶抑制,新靶点,嘌呤信号。
摘要: Ecto-5’-nucleotidase (ecto-5’-NT, 5’-NT, eN, CD73) is a membrane ectoenzyme that is primarily responsible for the extracellular production of adenosine from AMP. Ecto-5'-NT is overexpressed in various types of cancer cells, leading to elevated concentrations of adenosine in the tumour microenvironment. Adenosine has also been found to be important in cancer pathogenesis, showing strong immunosuppressive effects over antitumour T cells and macrophages and promoting neovascularization and cell adherence. These actions support tumour growth and development. It has been suggested that the inhibition of ecto-5’-NT results in lower extracellular concentrations of adenosine within the tumour microenvironment, which would directly affect cancer cells and render malignant cells more susceptible to host defence systems. Such mechanisms are proposed to represent promising new targets for cancer therapy. The aim of this review is to explore the biochemical and structural features of ecto-5’-NT, including a brief analysis of its active site by molecular modelling, as a means of evaluating whether the inhibition of this enzyme does indeed represent a feasible strategy for treating cancer. Known inhibitors and possible prototypes that could be used to target ecto-5’-NT during cancer therapy are also discussed.
Export Options
About this article
Cite this article as:
Patricia Frasson Corbelini, Fabricio Figueiro, Gustavo Machado das Neves, Saulo Andrade and Daniel Fabio Kawano, Ana Maria Oliveira Battastini and Vera Lucia Eifler-Lima , Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study, Current Medicinal Chemistry 2015; 22 (15) . https://dx.doi.org/10.2174/0929867322666150408112615
DOI https://dx.doi.org/10.2174/0929867322666150408112615 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Biodistribution and Pharmacokinetics of PEG-10kDa-Cholecystokinin-10 in Rats After Different Routes of Administration
Current Drug Delivery Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials The Effect of Drugs on the Labeling of Blood Elements with Technetium-99m
Current Pharmaceutical Design Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Inhibition of Proliferation of ECV304 Cells by a Disintegrin from Chinese Green Tree Viper
Protein & Peptide Letters Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Current Pharmaceutical Design Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents Preparation and Quality Control of <sup>111</sup>In-Plerixafor for Chemokine Receptor CXCR4
Recent Patents and Topics on Imaging (Discontinued)